Onward Therapeutics and Biomunex Pharmaceuticals Enter into a Worldwide Exclusive License and Co-development Agreement to a Bispecific Antibody for Immuno-Oncology

Corporate Breaking News

Home : Onward Therapeutics and Biomunex Pharmaceuticals Enter into a Worldwide Exclusive License and Co-development Agreement to a Bispecific Antibody for Immuno-Oncology

Feb 16 2021	Onward Therapeutics and Biomunex Pharmaceuticals Enter into a Worldwide Exclusive License and Co-development Agreement to a Bispecific Antibody for Immuno-Oncology
LAUSANNE, Switzerland, Feb. 16, 2021 /PR Newswire/ -- Onward Therapeutics SA (Onward) announced today the execution of a worldwide exclusive license and co-development agreement with Biomunex Pharmaceuticals SAS (Biomunex), Paris, France, of a bispecific antibody targeting two immune...


Source:https://www.prnewswire.com:443/news-releases/onward-therapeutics-and-biomunex-pharmaceuticals-enter-into-a-worldwide-exclusive-license-and-co-development-agreement-to-a-bispecific-antibody-for-immuno-oncology-301227987.html

Related News
» Respected industry leader Kathleen Abernathy appointed to BAI Communications Board of Directors » La prueba de COVID-19 de Seegene utilizando la muestra de saliva es tan efectiva como los de la muestra de hisopado nasofaríngeo